Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
18.01.2025 12:05:00
|
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: LLY) Mounjaro skyrocketing over the past year. However, Eli Lilly recently surprised investors when it cut its full-year revenue guidance ahead of an investor conference after sales of its GLP-1 drugs fell short of expectations.Eli Lilly now expects revenue to be approximately $13.5 billion for its fourth quarter and $45 billion for the full year 2024. The company had earlier forecast full-year revenue to come in between $45.4 billion to $46 billion. Analysts, meanwhile, were projecting Q4 revenue of $13.94 billion and full-year revenue of $45.49 billion, as compiled by LSEG. The new forecast from Lilly reflects 44% year-over-year revenue growth for the fourth quarter and 32% for the year. So the company is still seeing strong growth -- just not as robust as anticipated. It is also worth noting that Lilly's original full-year revenue guidance was for $41 billion, so it handily surpassed that. Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Eli Lilly | 726,20 | -3,73% |
|